search
Back to results

A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma

Primary Purpose

Melanoma, Malignant Melanoma, Metastatic Melanoma

Status
Terminated
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
131I-TM601
Sponsored by
TransMolecular
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Melanoma focused on measuring Melanoma, Malignant melanoma, metastatic melanoma, Phase 1, Phase 2

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Patient MUST:

  1. Have signed and dated written informed consent.
  2. Be aged ≥ 18 years old at time of informed consent.
  3. Have histologically proven Stage IIIc or IV malignant melanoma with documented progression during or following the most recent prior melanoma therapy.
  4. Have measurable disease, defined as lesions that can be accurately measured in at least one dimension as > 20 mm with conventional techniques (CT) or > 10 mm with spiral CT scan or brain MRI.
  5. Have failed at least 1 prior therapy for melanoma or refused first-line, standard therapy.
  6. Have an ECOG performance status of 0 - 1.
  7. Have a life expectancy, based on the Investigator's judgment, of > 3 months.
  8. On screening ECG, have a QTc interval of < 450 ms.
  9. If taking steroids, be on a dose that is stable for at least 5 days prior to the Imaging Dose.
  10. Have recovered from the toxicity of all previous therapy prior to enrollment. If the patient has undergone recent major surgery, an interval of at least 3 weeks must have elapsed between the surgery and the date of the Imaging Dose.
  11. Have acceptable laboratory results as follows:

    1. Hemoglobin ≥ 9g/dL
    2. ANC ≥ 1,500 mm3
    3. Platelet count ≥ 150,000 mm3
    4. PT <1.5 ULN
    5. PTT < 1.5 ULN
    6. Total Bilirubin < 2.0 mg/dL
    7. AST/ALT < or = 5 ULN
    8. Serum Creatinine < or = 2 mg/dL
  12. Have a negative serum pregnancy test within 14 days of study drug administration, if female and of child bearing potential.
  13. Agree to use an effective form of contraception to avoid pregnancy, if fertile (applicable to both male and female patients).
  14. Agree to refrain from nursing, if female.
  15. Be able to comply with treatment plan, study procedures, and follow-up examinations.

    If enrolled in the single site Sub-Study, patient MUST:

  16. Have at least one accessible biopsy site and a second measurable target site per RECIST criteria.
  17. Agree to pre-infusion and post-infusion biopsies of tumor lesions.

Exclusion Criteria:

Patient May Not:

  1. Have a serious concurrent infection or medical illness which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety. Examples of medical illnesses include, but are not limited to, the following: uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, known history of HIV, Hepatitis B or Hepatitis C infection, or psychiatric illness/social situation which would limit compliance with study requirements.
  2. Have CNS metastases, unless, in the PI's judgment, the CNS involvement is stable and not likely to require further palliative therapy to the CNS during the course of the treatment protocol. If previous treatment has included radiotherapy, CNS disease should be stable at least 6 weeks from receipt of previous radiotherapy.
  3. Have a prior malignancy with less than 3-year disease-free interval, except for adequately treated basal cell or squamous cell carcinoma of the skin, or in situ cancer of the cervix.
  4. Have received radiation treatments < 6 weeks prior to first study drug administration (Imaging Dose).
  5. Have previously received radiation to ≥ 25% red bone marrow.
  6. Have received any cytotoxic chemotherapy, hormonal therapy, or immunotherapy, whether conventional or investigational, < 4 weeks prior to receiving the first study drug (Imaging Dose) administration in this study (6 weeks for mitomycin-C or nitrosoureas).
  7. Have a history of pulmonary embolism within 1 year or deep venous thrombosis within six months of study enrollment.
  8. Current or recent history of high-dose aspirin, warfarin, or heparin use (Aspirin < or = 81 mg/day, low-dose warfarin < 1 mg/day, or low-dose heparin for IV catheter patency is allowed).
  9. Received investigational agents within 4 weeks prior to receiving the first study drug (Imaging Dose) administration in this study.
  10. Have a history of allergic reactions attributed to compounds of similar chemical or biological composition to 131I-TM601 e.g. iodine or iodine-containing drugs.

Sites / Locations

  • Lacks Cancer Center
  • New York University School of Medicine
  • Mary Crowley Cancer Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

1

Arm Description

Outcomes

Primary Outcome Measures

Safety profile, as evaluated by incidence, severity, duration, causality, and seriousness of adverse events as well as by changes in patient's physical examination, vital signs, and clinical laboratory assessments.
6 month progression-free survival

Secondary Outcome Measures

Clinical response, time to disease progression, and overall survival.

Full Information

First Posted
August 11, 2008
Last Updated
May 8, 2009
Sponsor
TransMolecular
search

1. Study Identification

Unique Protocol Identification Number
NCT00733798
Brief Title
A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma
Official Title
A Phase 1/2, Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients With Progressive and/or Recurrent Malignant Melanoma
Study Type
Interventional

2. Study Status

Record Verification Date
May 2009
Overall Recruitment Status
Terminated
Why Stopped
For Strategic Reasons
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
TransMolecular

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of 131I-TM601 in the treatment of adult patients with progressive and/or recurrent malignant melanoma.
Detailed Description
This is a multi-center, Phase 1/2 study evaluating the use of multiple intravenous doses of 131I-TM601 in adults patients with progressive and/or recurrent malignant melanoma (Stage IIIc or IV) with measurable disease who have failed first line/standard therapy. The study will be conducted in 2 phases. During the first, Dose Escalation Phase, eligible patients wil be assigned in groups of 3-6 (depending upon the treatment response seen at each dose) to dose cohorts of between 2-5 weekly IV doses of 131I-TM601. Escalation to the next highest dose during the Dose Escalation Phase will be dependent upon demonstrated tolerance in the previous dosing group. In the second, Efficacy Phase, all patients will be treated with the Maximum Tolerated Dose determined in the Dose Escalation Phase. Prior to initiating treatment, all patients will be administered a single imaging dose of 131I-TM601, IV, as an Imaging Dose to evaluate tumor uptake. Only patients demonstrating tumor uptake will remain on the study. Patients in both study phases will have safety parameters evaluated continuously throughout the study. Clinical response to 131I-TM601 will be assessed in each study patient at 28 days following the final study dose, and then at 2-month intervals, starting at 3 months following the first study dose (during the first year of follow-up), and finally at 3-month intervals thereafter until disease progression.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Melanoma, Malignant Melanoma, Metastatic Melanoma
Keywords
Melanoma, Malignant melanoma, metastatic melanoma, Phase 1, Phase 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
58 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
131I-TM601
Other Intervention Name(s)
chlorotoxin
Intervention Description
After a single 20mCi/0.4 mg Imaging Dose of 131I-TM601, patients in the Dose Escalation Phase will be administered between 2-5 weekly doses of 131I-TM601 at 1.2 mCi/kg of lean body mass (specific activity of 131I-TM601 will be maintained at 50 mCi 131I/mg TM601 for all doses administered in this study.) Patients in the Efficacy Phase of the study will be treated at the Maximum Tolerated Dose established in the Dose Escalation Phase.
Primary Outcome Measure Information:
Title
Safety profile, as evaluated by incidence, severity, duration, causality, and seriousness of adverse events as well as by changes in patient's physical examination, vital signs, and clinical laboratory assessments.
Time Frame
duration of the study
Title
6 month progression-free survival
Time Frame
duration of study
Secondary Outcome Measure Information:
Title
Clinical response, time to disease progression, and overall survival.
Time Frame
duration of study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient MUST: Have signed and dated written informed consent. Be aged ≥ 18 years old at time of informed consent. Have histologically proven Stage IIIc or IV malignant melanoma with documented progression during or following the most recent prior melanoma therapy. Have measurable disease, defined as lesions that can be accurately measured in at least one dimension as > 20 mm with conventional techniques (CT) or > 10 mm with spiral CT scan or brain MRI. Have failed at least 1 prior therapy for melanoma or refused first-line, standard therapy. Have an ECOG performance status of 0 - 1. Have a life expectancy, based on the Investigator's judgment, of > 3 months. On screening ECG, have a QTc interval of < 450 ms. If taking steroids, be on a dose that is stable for at least 5 days prior to the Imaging Dose. Have recovered from the toxicity of all previous therapy prior to enrollment. If the patient has undergone recent major surgery, an interval of at least 3 weeks must have elapsed between the surgery and the date of the Imaging Dose. Have acceptable laboratory results as follows: Hemoglobin ≥ 9g/dL ANC ≥ 1,500 mm3 Platelet count ≥ 150,000 mm3 PT <1.5 ULN PTT < 1.5 ULN Total Bilirubin < 2.0 mg/dL AST/ALT < or = 5 ULN Serum Creatinine < or = 2 mg/dL Have a negative serum pregnancy test within 14 days of study drug administration, if female and of child bearing potential. Agree to use an effective form of contraception to avoid pregnancy, if fertile (applicable to both male and female patients). Agree to refrain from nursing, if female. Be able to comply with treatment plan, study procedures, and follow-up examinations. If enrolled in the single site Sub-Study, patient MUST: Have at least one accessible biopsy site and a second measurable target site per RECIST criteria. Agree to pre-infusion and post-infusion biopsies of tumor lesions. Exclusion Criteria: Patient May Not: Have a serious concurrent infection or medical illness which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety. Examples of medical illnesses include, but are not limited to, the following: uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, known history of HIV, Hepatitis B or Hepatitis C infection, or psychiatric illness/social situation which would limit compliance with study requirements. Have CNS metastases, unless, in the PI's judgment, the CNS involvement is stable and not likely to require further palliative therapy to the CNS during the course of the treatment protocol. If previous treatment has included radiotherapy, CNS disease should be stable at least 6 weeks from receipt of previous radiotherapy. Have a prior malignancy with less than 3-year disease-free interval, except for adequately treated basal cell or squamous cell carcinoma of the skin, or in situ cancer of the cervix. Have received radiation treatments < 6 weeks prior to first study drug administration (Imaging Dose). Have previously received radiation to ≥ 25% red bone marrow. Have received any cytotoxic chemotherapy, hormonal therapy, or immunotherapy, whether conventional or investigational, < 4 weeks prior to receiving the first study drug (Imaging Dose) administration in this study (6 weeks for mitomycin-C or nitrosoureas). Have a history of pulmonary embolism within 1 year or deep venous thrombosis within six months of study enrollment. Current or recent history of high-dose aspirin, warfarin, or heparin use (Aspirin < or = 81 mg/day, low-dose warfarin < 1 mg/day, or low-dose heparin for IV catheter patency is allowed). Received investigational agents within 4 weeks prior to receiving the first study drug (Imaging Dose) administration in this study. Have a history of allergic reactions attributed to compounds of similar chemical or biological composition to 131I-TM601 e.g. iodine or iodine-containing drugs.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Gribbin, MD
Organizational Affiliation
Lacks Cancer Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Neil Senzer, MD
Organizational Affiliation
Mary Crowley Cancer Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Anna Pavlick, DO
Organizational Affiliation
New York University Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Lacks Cancer Center
City
Grand Rapids
State/Province
Michigan
ZIP/Postal Code
49503
Country
United States
Facility Name
New York University School of Medicine
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Facility Name
Mary Crowley Cancer Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
16877732
Citation
Mamelak AN, Rosenfeld S, Bucholz R, Raubitschek A, Nabors LB, Fiveash JB, Shen S, Khazaeli MB, Colcher D, Liu A, Osman M, Guthrie B, Schade-Bijur S, Hablitz DM, Alvarez VL, Gonda MA. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol. 2006 Aug 1;24(22):3644-50. doi: 10.1200/JCO.2005.05.4569.
Results Reference
background
PubMed Identifier
15809479
Citation
Hockaday DC, Shen S, Fiveash J, Raubitschek A, Colcher D, Liu A, Alvarez V, Mamelak AN. Imaging glioma extent with 131I-TM-601. J Nucl Med. 2005 Apr;46(4):580-6.
Results Reference
background
PubMed Identifier
12112367
Citation
Lyons SA, O'Neal J, Sontheimer H. Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia. 2002 Aug;39(2):162-73. doi: 10.1002/glia.10083.
Results Reference
background
PubMed Identifier
17335414
Citation
Mamelak AN, Jacoby DB. Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv. 2007 Mar;4(2):175-86. doi: 10.1517/17425247.4.2.175.
Results Reference
background

Learn more about this trial

A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma

We'll reach out to this number within 24 hrs